Related Experiment Video
Updated: Apr 17, 2026
Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma
Published on: November 5, 2020
Molecular landscape of pancreatic cancer: implications for current clinical trials
Gregory M Heestand1, Razelle Kurzrock1
1Center for Personalized Cancer Therapy, Division of Hematology and Oncology, University of California, San Diego, La Jolla, California, 92093, U.S.A.
Abstract:
Despite recent improvements, overall survival for advanced adenocarcinoma of the pancreas continues to be poor. In comparison to other tumor types that have enjoyed marked survival benefit by targeting aberrant cell signaling pathways, standard of care treatment for pancreatic cancer is limited to conventional cytotoxic chemotherapy. Multiple pathway aberrations have been documented in pancreatic cancer. A review of the COSMIC database reveals that most pancreatic cancers contain somatic mutations, with the five most frequent being KRAS, TP53, CDKN2A, SMAD4, and ARID1A, and multiple other abnormalities seen including, but not limited to, mutations in STK11/LKB1, FBXW7, PIK3CA, and BRAF. In the era of tumor profiling, these aberrations may provide an opportunity for new therapeutic approaches. Yet, searching clinicaltrials.gov for recent drug intervention trials for pancreatic adenocarcinoma, remarkably few (10 of 116 (8.6%)) new study protocols registered in the last three years included a molecular/biomarker stratification strategy. Enhanced efforts to target subsets of patients with pancreatic cancer in order to optimize therapy benefit are warranted.
Insights
Pancreatic cancer survival remains poor despite advances. Targeting specific genetic mutations, common in pancreatic tumors, could improve treatment efficacy, but few trials currently use this approach.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Advanced pancreatic adenocarcinoma has a poor prognosis, with limited treatment options beyond conventional chemotherapy.
- Unlike other cancers benefiting from targeted therapies, pancreatic cancer treatment has not widely adopted pathway-specific approaches.
- Frequent somatic mutations (KRAS, TP53, CDKN2A, SMAD4, ARID1A) are present in pancreatic cancers, offering potential therapeutic targets.
Purpose of the Study:
- To highlight the potential of targeting molecular aberrations in pancreatic cancer.
- To assess the current integration of molecular/biomarker stratification in clinical trials for pancreatic adenocarcinoma.
Main Methods:
- Reviewed the COSMIC database for common pancreatic cancer mutations.
- Searched clinicaltrials.gov for recent pancreatic adenocarcinoma drug intervention trials (last three years).
Main Results:
- Identified frequent somatic mutations in pancreatic cancer, including KRAS, TP53, CDKN2A, SMAD4, and ARID1A.
- Found that only a small fraction (8.6%) of recent pancreatic adenocarcinoma trials incorporated molecular/biomarker stratification.
Conclusions:
- Despite identified molecular targets, current clinical trial strategies for pancreatic cancer lag in utilizing personalized approaches.
- Enhanced efforts are needed to develop and implement targeted therapies based on tumor profiling to improve patient outcomes.
